Exchange: NYSE·Updated 07:30 PM EST

AVTR News

News
all
press releases
Avantor (NYSE:AVTR) Cut to Buy at Wall Street Zen
Wall Street Zen lowered Avantor from a "strong-buy" rating to a "buy" rating in a research note on Sunday...
MarketBeat
Avantor (NYSE:AVTR) Cut to Buy at Wall Street Zen
Wall Street Zen lowered Avantor from a "strong-buy" rating to a "buy" rating in a research note on Sunday...
MarketBeat
More News
Does Avantor, Inc. (AVTR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Avantor (AVTR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Here is how Avantor, Inc. (AVTR) and Novartis (NVS) have performed compared to their sector so far this year.
Zacks
Avantor (NYSE:AVTR) reported third-quarter financial results on Wednesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. Forread more...
Benzinga
Avantor (AVTR) delivered earnings and revenue surprises of +4.76% and +3.53%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Avantor Reports Third Quarter 2026 Results Avantor Reports Third Quarter 2026 ResultsPR NewswireRADNOR, Pa., Oct. 28, 2026 Net sales of $1,698.3 million; increase of 4.6%; organic increase of 5.2%Diluted GAAP EPS of $0.30; adjusted EPS of $0.22Raised FY 2026 organic revenue growth, adjusted EPS and...
PR Newswire
Avantor appoints new Chief Information Officer Avantor appoints new Chief Information OfficerPR NewswireRADNOR, Pa., Oct. 26, 2026 RADNOR, Pa., Oct. 26, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life...
PR Newswire
Healthcare stocks are heating up, and investors have a fresh lineup of catalysts to watch. Pfizer (NYSE:PFE) is pushing its oncology story back into the spotlight, while NeOnc Technologies Holdings (NASDAQ:NTHI) is emerging as a high-volatility biotech to watch as brain-cancer milestones, Abu Dhabi expansion and a battle around key technical levels converge. Avantor (NYSE:AVTR) faces a crucial earnings test that could determine whether its recovery has more room to run, while Eli Lilly and Co (NYSE:LLY) is building on its blockbuster drug franchise with encouraging new pediatric clinical data. Takeda Pharmaceutical (NYSE:TAK) brings global pipeline potential and diversified drug-market exposure to the mix, while MoonLake Immunotherapeutics (NASDAQ:MLTX) is drawing trader attention with active trading putting its next potential catalyst under the microscope.
24-7 Market News
AVTR's improving commercial execution, specialty product strength and raised 2026 outlook signal recovery potential despite lingering demand challenges.
Zacks

Advertisement|Remove ads.